226.91 0.00 (0.00%)
After hours: 4:43PM EDT
|Bid||226.81 x 800|
|Ask||228.12 x 800|
|Day's Range||225.71 - 230.54|
|52 Week Range||170.56 - 244.99|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||17.76|
|Earnings Date||Jul 23, 2020 - Jul 27, 2020|
|Forward Dividend & Yield||6.40 (2.79%)|
|Ex-Dividend Date||May 15, 2020|
|1y Target Est||252.21|
Clinical trials of non-COVID-19 drugs have taken a backseat as most drugmakers and biotechnology companies are speeding up development of a vaccine for the novel coronavirus.
The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global
Investors have been bullish on biotech, in the hope that companies will soon come up with a treatment, cure, or vaccine for Covid-19. But there’s more to biotech than the coronavirus, and even though these ETFs have risen, they could have farther to go.
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech companies Amgen and Alexion Pharmaceuticals reached an agreement in a patent battle over blockbuster rare-disease drug Soliris. ALXN stock popped Thursday and Friday.
Amgen (NASDAQ:AMGN) today announced new data from the CodeBreaK 100 clinical development program evaluating investigational AMG 510 (proposed INN sotorasib) in heavily pretreated patients with a range of KRAS G12C-mutant solid tumors. Updated Phase 1 data from patients with advanced colorectal cancer (CRC) and other selected solid tumors continued to demonstrate disease control activity, safety and tolerability. These data are being presented during the ASCO20 Virtual Scientific Program, May 29 – 31, 2020.
If stocks do pause, a good setup is to look for quality stocks that are pulling back to key moving averages. One stock fitting that criteria is Amgen, the biotech giant. Amgen stock rallied from a low point near 175 all the way up to 245 and is now sitting near the 50- and 200-day moving averages.
Amgen (NASDAQ: AMGN) will present at the Jefferies 2020 Virtual Healthcare Conference at 4:00 p.m. ET on Tuesday, June 2, 2020. David M. Reese, M.D., executive vice president of Research and Development at Amgen, will be leading the presentation. Live audio of the fireside chat can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
The stock market continued to gain ground at midday on Thursday, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) participated in the modest rally. Slightly before noon EDT, the index was up just over half a percent, as was the Nasdaq 100 Index of top stocks on the exchange. Workday (NASDAQ: WDAY) and Alexion Pharmaceuticals (NASDAQ: ALXN) rose for different reasons, but their gains were among the leaders in the Nasdaq 100 and showed the broad-based support that the rally has had recently.
Amgen has challenged Alexion’s exclusive rights to its blockbuster drug Soliris, a move that has been a significant worry for Alexion investors. A judge wrote Wednesday that the parties have reached an agreement in principle.
In this article we will check out the progression of hedge fund sentiment towards Amgen, Inc. (NASDAQ:AMGN) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 […]
Amgen stock is consolidating as it takes a two-pronged approach to coronavirus treatment, partnering with Adaptive Biotechnologies and testing Otezla in Covid-19. Is Amgen stock a buy?
Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the ASCO20 Virtual Scientific Program on Friday, May 29, at 1:00 p.m. PT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate to discuss Amgen's oncology program, including data being presented on the Company's KRASG12C inhibitor sotorasib.
Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.
Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders on May 20, 2020, held virtually this year due to the COVID-19 pandemic. More than 88 percent of outstanding shares were represented at the meeting.
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
Head of Macro Strategy at Academy Securities Peter Tchir joins Yahoo Finance’s Seana Smith to break down his outlook on the markets as coronavirus cases surpass 1.5M in the U.S., according to John Hopkins.
Amgen (AMGN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The American Society of Clinical Oncology released abstracts of the papers set to be presented at its coming meeting. Analysts and investors are combing through the documents for key developments.
The first-quarter earnings season has revealed how quickly companies are embracing digital and automation strategies, as they shift to dealing with consumers who are complying with stay-at-home rules and other restrictions on movement during the coronavirus pandemic.
The Dow Jones is making an important pullback since bottoming in late March. Fed Chair Jerome Powell's speech renewed focus on economic challenges.
Amgen (NASDAQ: AMGN) investors who were patient in February when the company's year-end numbers were down slightly were rewarded late last month when the Thousand Oaks, Calif., biotech giant's first-quarter 2020 results came out. The company's biggest riser was psoriasis drug Otezla, which had $479 million in sales in its first year since the company bought it for $13.4 billion from Celgene. Most of the company's old standbys continue to bring in strong sales, led by anti-inflammatory drug Enbrel with $1.15 billion.